SCHEMBL4625629

SCHEMBL4625629

O=C(O)C(Cc1ccc2nc(-c3c(Cl)cccc3Cl)ccc2c1)NS(=O)(=O)c1c(Cl)cccc1Cl

nearest known ligand 0.69

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ITGAV P06756 6/20 0.69
ITGB1 P05556 5/20 0.69
LMNA P02545 1/20 0.47
PKM P14618 1/20 0.47
ITGA4 P13612 4/20 0.45
ITGB7 P26010 4/20 0.45
HTT P42858 1/20 0.42
ABL1 P00519 1/20 0.41
SLC1A3 P43003 1/20 0.41
SLC1A2 P43004 1/20 0.41
ITGB3 P05106 5/20 0.40
MMP2 P08253 4/20 0.40
ADAMTS5 Q9UNA0 1/20 0.40
ITGA2B P08514 1/20 0.39
MMP9 P14780 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4625367 0.89 ITGAV (0.55) ITGAVITGB1LMNAPKMHTT
SCHEMBL4626503 0.84 ITGB1 (0.76) ITGAVITGB1ITGA4ITGB7ABL1
SCHEMBL4626491 0.82 ITGB1 (0.73) ITGAVITGB1ITGA4ITGB7ABL1
SCHEMBL8352229 0.82 ITGB1 (1.00) ITGAVITGB1ITGA4ITGB7
SCHEMBL3313356 0.82 ITGB1 (1.00) ITGAVITGB1ITGA4ITGB7
SCHEMBL3316398 0.82 ITGB1 (1.00) ITGAVITGB1ITGA4ITGB7
SCHEMBL3313373 0.82 ITGB1 (1.00) ITGAVITGB1ITGA4ITGB7
SCHEMBL4419511 0.81 ITGB1 (0.83) ITGAVITGB1ITGA4ITGB7ITGB3
SCHEMBL3320942 0.80 ITGB1 (0.78) ITGAVITGB1ITGA4ITGB7ABL1
SCHEMBL4625568 0.80 ITGB1 (0.68) ITGAVITGB1ITGA4ITGB7ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501801-B1 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF VLA-4 DEPENDENT DISEASES UCB PHARMA SA (BE) 2008-01-23 EP disclosed
EP-1870402-A1 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors UCB Pharma, S.A. (BE) 2007-12-26 EP disclosed